✦ LIBER ✦

6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens

✍ Scribed by Sobrero, A.F.; Pessino, A.; Andretta, V.; Bennicelli, E.; Fornarini, G.; Caprioni, F.; Comandini, D.; Orsino, L.; Lambiase, A.; Bordignon, C.

Book ID: 122013019
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71161-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6062 NGR-hTNF, a vascular targeting agen

6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study

✍ Rimassa, L.; Santoro, A.; Sobrero, A.F.; Sclafani, F.; Gregorc, V.; Andretta, V. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase II study of NGR-hTNF, a selective

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

✍ Armando Santoro; Lorenza Rimassa; Alberto F. Sobrero; Giovanni Citterio; Frances 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 206 KB